Incyte's vision is to become a leading drug discovery and development company by building a proprietary product pipeline of novel small molecule drugs in serious unmet medical needs.

We have an experienced management, discovery, clinical development and commercial team. Our assets, experience and prior success in bringing important new drugs to market put us in a strong position to make a difference in healthcare, improve the lives of patients and build significant sustainable value for our shareholders.

Our pipeline is focused in oncology and inflammation and includes compounds in various stages of development. In June 2011 we submitted a New Drug Application (NDA) for our most advanced product candidate, ruxolitinib, for the treatment of myelofibrosis.  Should this application be approved, we could potentially launch our first commercial product late in 2011.

We have established multiple collaborations with major pharmaceutial companies to support the clinical development and global commercialization of several of our compounds. Through strategic alliances with Novartis and Lilly, we are advancing the global development of two of our JAK 1 and JAK 2 inhibitor programs.